Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.

Huang M, Lopes GL, Insinga RP, Burke T, Ejzykowicz F, Zhang Y, Feliciano JL.

Immunotherapy. 2019 Dec;11(17):1463-1478. doi: 10.2217/imt-2019-0178. Epub 2019 Nov 18.

2.

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.

Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC.

Pharmacoecon Open. 2019 Sep 17. doi: 10.1007/s41669-019-00178-7. [Epub ahead of print]

3.

Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.

Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Ejzykowicz F, Burke T.

Curr Med Res Opin. 2019 Jul;35(7):1241-1256. doi: 10.1080/03007995.2019.1571297. Epub 2019 Jan 29.

PMID:
30649973
4.

Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.

Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T.

J Med Econ. 2018 Dec;21(12):1191-1205. doi: 10.1080/13696998.2018.1521416. Epub 2018 Sep 21.

PMID:
30188231
5.

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.

Borse RH, Kachroo S, Brown C, McCann E, Insinga RP.

Rheumatol Ther. 2018 Jun;5(1):57-73. doi: 10.1007/s40744-018-0108-4. Epub 2018 Apr 9.

7.

EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.

Stafford MR, Hareendran A, Ng-Mak DS, Insinga RP, Xu R, Stull DE.

Health Qual Life Outcomes. 2012 Jun 12;10:65. doi: 10.1186/1477-7525-10-65.

8.

Costs associated with outpatient, emergency room and inpatient care for migraine in the USA.

Insinga RP, Ng-Mak DS, Hanson ME.

Cephalalgia. 2011 Nov;31(15):1570-5. doi: 10.1177/0333102411425960. Epub 2011 Oct 19.

PMID:
22013140
9.

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Muñoz N, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96. doi: 10.1158/1055-9965.EPI-10-0791.

10.

EuroQol (EQ-5D) health utility scores for patients with migraine.

Xu R, Insinga RP, Golden W, Hu XH.

Qual Life Res. 2011 May;20(4):601-8. doi: 10.1007/s11136-010-9783-5. Epub 2010 Nov 10.

PMID:
21063786
11.

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235.

12.

Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population.

Henk HJ, Insinga RP, Singhal PK, Darkow T.

J Low Genit Tract Dis. 2010 Jan;14(1):29-36. doi: 10.1097/LGT.0b013e3181ac05e9.

PMID:
20040833
13.

Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW.

Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000.

PMID:
19757871
14.

Assessing incidence and economic burden of genital warts with data from a US commercially insured population.

Hoy T, Singhal PK, Willey VJ, Insinga RP.

Curr Med Res Opin. 2009 Oct;25(10):2343-51. doi: 10.1185/03007990903136378.

PMID:
19650749
16.

Human papillomavirus infections and vulvar disease development.

Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1777-84. doi: 10.1158/1055-9965.EPI-09-0067.

17.

Age-based programs for vaccination against HPV.

Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E.

Value Health. 2009 Jul-Aug;12(5):697-707. doi: 10.1111/j.1524-4733.2009.00512.x.

18.

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.

Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):459-66.

19.

A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.

Ruchlin HS, Insinga RP.

Pharmacoeconomics. 2008;26(11):925-35. Review.

PMID:
18850762
20.

A multi-type HPV transmission model.

Elbasha EH, Dasbach EJ, Insinga RP.

Bull Math Biol. 2008 Nov;70(8):2126-76. doi: 10.1007/s11538-008-9338-x. Epub 2008 Oct 8.

PMID:
18841421
21.

Structural differences among cost-effectiveness models of human papillomavirus vaccines.

Insinga RP, Dasbach EJ, Elbasha EH.

Expert Rev Vaccines. 2008 Sep;7(7):895-913. doi: 10.1586/14760584.7.7.895.

PMID:
18767941
22.

Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.

Insinga RP, Ye X, Singhal PK, Carides GW.

Gynecol Oncol. 2008 Nov;111(2):188-96. doi: 10.1016/j.ygyno.2008.07.032. Epub 2008 Aug 30.

PMID:
18757080
23.

Five-year routine cervical cancer screening rates and intervals in a US health plan.

Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA.

Curr Med Res Opin. 2008 Sep;24(9):2429-35. doi: 10.1185/03007990802281671 . Epub 2008 Jul 24.

PMID:
18662493
24.

A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.

Insinga RP, Liaw KL, Johnson LG, Madeleine MM.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22. doi: 10.1158/1055-9965.EPI-07-2922. Review.

25.

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

Dasbach EJ, Insinga RP, Elbasha EH.

BJOG. 2008 Jul;115(8):947-56. doi: 10.1111/j.1471-0528.2008.01743.x. Epub 2008 May 22.

26.

Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.

Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER.

Value Health. 2008 Dec;11(7):1022-32. doi: 10.1111/j.1524-4733.2008.00342.x. Epub 2008 May 16.

27.

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.

Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM.

Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.

PMID:
18313445
28.

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM.

Vaccine. 2007 Dec 21;26(1):128-39. Epub 2007 Nov 20.

PMID:
18055075
29.

Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.

Infect Agent Cancer. 2007 Jul 12;2:15.

30.

Abnormal outcomes following cervical cancer screening: event duration and health utility loss.

Insinga RP, Glass AG, Myers ER, Rush BB.

Med Decis Making. 2007 Jul-Aug;27(4):414-22. Epub 2007 Jun 21.

PMID:
17585005
31.

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):709-15.

32.

Model for assessing human papillomavirus vaccination strategies.

Elbasha EH, Dasbach EJ, Insinga RP.

Emerg Infect Dis. 2007 Jan;13(1):28-41.

33.

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Insinga RP, Itzler RF, Pellissier JM.

Pharmacoeconomics. 2007;25(2):155-69.

PMID:
17249857
34.

Annual productivity costs due to cervical cancer mortality in the United States.

Insinga RP.

Womens Health Issues. 2006 Sep-Oct;16(5):236-42.

PMID:
17055376
35.

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.

Dasbach EJ, Elbasha EH, Insinga RP.

Epidemiol Rev. 2006;28:88-100. Epub 2006 Jun 1. Review.

PMID:
16740585
36.

Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201].

Insinga RP, Glass AG, Rush BB.

Health Policy. 2006 Aug;77(3):245-6. Epub 2005 Nov 16. No abstract available.

PMID:
16297495
38.

The incidence of herpes zoster in a United States administrative database.

Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA.

J Gen Intern Med. 2005 Aug;20(8):748-53.

39.

The health care costs of cervical human papillomavirus--related disease.

Insinga RP, Glass AG, Rush BB.

Am J Obstet Gynecol. 2004 Jul;191(1):114-20.

PMID:
15295351
40.

Diagnoses and outcomes in cervical cancer screening: a population-based study.

Insinga RP, Glass AG, Rush BB.

Am J Obstet Gynecol. 2004 Jul;191(1):105-13.

PMID:
15295350
41.

Pap screening in a U.S. health plan.

Insinga RP, Glass AG, Rush BB.

Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):355-60.

42.

Understanding differences between self-ratings and population ratings for health in the EuroQOL.

Insinga RP, Fryback DG.

Qual Life Res. 2003 Sep;12(6):611-9.

PMID:
14516171
43.

The health and economic burden of genital warts in a set of private health plans in the United States.

Insinga RP, Dasbach EJ, Myers ER.

Clin Infect Dis. 2003 Jun 1;36(11):1397-403. Epub 2003 May 19.

PMID:
12766834
44.

Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.

Insinga RP, Laessig RH, Hoffman GL.

J Pediatr. 2002 Oct;141(4):524-31. Erratum in: J Pediatr. 2003 Jan;142(1):56..

PMID:
12378192
45.

Trends in malignant melanoma incidence and mortality in Wisconsin, 1979-1997.

Insinga RP, Reither EN, Remington PL, Stephenson-Vine L.

WMJ. 2001;100(6):27-31.

PMID:
11688336

Supplemental Content

Loading ...
Support Center